Share Name Share Symbol Market Type Share ISIN Share Description
Genuit Group Plc LSE:GEN London Ordinary Share GB00BKRC5K31 ORD GBP0.001
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 603.00 0.00 00:00:00
Bid Price Offer Price High Price Low Price Open Price
601.00 603.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Industrial Engineering 398.60 23.80 8.50 70.9 1,496
Last Trade Time Trade Type Trade Size Trade Price Currency
18:49:22 O 3,068 603.00 GBX

Genuit (GEN) Latest News

More Genuit News
Genuit Investors    Genuit Takeover Rumours

Genuit (GEN) Discussions and Chat

Genuit Forums and Chat

Date Time Title Posts
16/11/202122:18Genuit Group51
19/11/200619:49GEN - SILLY PRICE500
26/8/200404:32Watching closely-
07/8/200313:33Anyone here invested in Generics?3
10/4/200216:16Further gloom for Generics UK4

Add a New Thread

Genuit (GEN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Genuit trades in real-time

Genuit (GEN) Top Chat Posts

Genuit Daily Update: Genuit Group Plc is listed in the Industrial Engineering sector of the London Stock Exchange with ticker GEN. The last closing price for Genuit was 603p.
Genuit Group Plc has a 4 week average price of 566p and a 12 week average price of 566p.
The 1 year high share price is 805p while the 1 year low share price is currently 450.50p.
There are currently 248,169,282 shares in issue and the average daily traded volume is 247,380 shares. The market capitalisation of Genuit Group Plc is £1,496,460,770.46.
scooper72: Looks like Aberdeen Standard Investments who hold 10.96 percent have cut their holding by about 10 percent and sold 2.3M shares last month. And I guess there must be others with large holding taking some profits. I'm now down an annoying 14 percent on my current holding in my SIPP having sold out previously at 688p with my original larger holding in my ISA. But thinking it is a bit late to comfortably take the £300 loss without worrying about doubly kicking myself if the price recovers. Today's drop seems hard to understand when considering the results out this morning looked ok
dope007: Input costs are definitely not past their peak. Additionally the industry is seeing further raw material shortage issues. Order books are full but at some point these horrendous input price rises are going to lead to reducing orders. However Genuit are in a better place than the window boys with less reliance on the home replacement mkt were at some point a home owner is going to say nope, not paying that...
scooper72: Do you see these factors averaging out in terms of when they announce their profits or do you see the share price pulling back further on results whenever they come out. Ok kicking myself for going back in a bit early and just wondering where fair value is currently.
dope007: Like the rest of our industry 2 dynamics are at play 1) Raw mat massive price hikes and ongoing/rolling shortages 2) High demand so selling everything they can produce even at higher prices
philanderer: Yesterday's Deutsche note.. (Sharecast News) - Analysts at Deutsche Bank raised their target price on plastic piping manufacturer Genuit from 653.0p to 708.0p on Wednesday, citing the group's "strong" first-half performance Deutsche Bank pointed to Genuit's adjusted interim operating profit of £48.6m, eclipsing its 2019 first-half performance by roughly 24% as it primary reason for the upgrade but also noted that the company appeared to be continuing to trade well, prompting a rise in management's expectations for the full year. "We raise our 2021-2023E operating profit forecasts by 4-7% and our target price by circa 8%," said the German bank, which also reiterated its 'buy' rating on the stock. "The company remains a strong performer, with recent acquisitions operating at or above expectations (three in February alone indicative of a team that does not let the grass grow under its feet)."
philanderer: Keyno, it seems to be bouncing back. Maybe helped by this? Genuit Group: Deutsche Bank keeps at buy and raises target price from 653.0p to 708.0p.
philanderer: Genuit Group: Berenberg reiterates hold with a target price of 630p.
rambutan2: we hold a small stake (see header)... Nanoscience Like many smaller AIM-listed investment vehicles, Nanoscience is playing a high stakes poker game where a real result from just one of its venture-backed biotechnology subsidiaries could send its share price soaring. Nanoscience listed on Aim last March, and is trading at 8.50p, from a high of around 17p last year. However, experts are particularly impressed by the potential for one of its investments – Imperial College spin-out Toumaz Technology Limited, which is developing a revolutionary vital signs monitoring system for patients. If tests in the first quarter of next year are successful, Toumaz will produce a battery-powered vital signs monitor, so tiny patients will be able to wear it in a bandage or plaster, that will continuously transmit back to doctors for five days. Nanoscience paid £17.1m for Toumaz, raising an additional £7.1m in development funding, helping to push it to a pre-tax loss of £2.5m in the six months to 29th September. The AIM vehicle has made a series of other acquisitions including a 2.9 per cent stake in Swedish gas sensing development company Applied Sensor Sweden. Presenting its interim results the company promised a "period of continuing and rapid evolution towards commercialisation". Buy. http://www.telegraph.co.uk/money/main.jhtml?xml=/money/2006/11/19/cxequit19.xml
ariane: Interim Results RNS Number:5593Q Generics Group AG 30 August 2005 30 August 2005 THE GENERICS GROUP AG ('GENERICS') INTERIM RESULTS 2005 Generics, a leading integrated technology consulting, development and investment organisation, today announces its results for the six months to 30 June 2005. Highlights: * Turnover increased by 28% to #10.7m (H1 2004: #8.3m) * Consulting and IP exploitation activities reported operating profit of #0.3m (H1 2004 loss of #0.1m) while increasing fee income by 34% * Operating loss for the Group of #0.9m (H1 2004 loss of #2.1m) after expensed costs of spinouts of #0.6m * Portfolio BVCA valuation of #12.5m (Q1 2005: #11.9m) * Cash balance of #3.6m (Q4 2004: #5.1m) before proceeds of #1.05m from the disposal of Imerge Ltd * Generics' spinout CMR Fuel Cells Ltd received the 2005 Carbon Trust award as Innovator of the year and in addition was a winner of the Individual and Small Business of the Year category * Successful completions of #4m financing by Sphere Medical Holding Ltd, originally Generics' medical device joint venture with Siemens, and #2.3m financing by CMR Fuel Cells Ltd * Launch of SGAI Tech Ltd, Scientific Generics' Hong Kong based joint venture * Adjusted losses per share of 0.5 pence (2004 loss of 1.0 pence) * Net assets per share of 8.7p per share (H1 2004: 9.4p) before taking into account the BVCA portfolio valuation uplift equivalent to 3.5p per share (H1 2004: 3.0p) On 11 August 2005 Generics announced that it had completed the sale of its shareholding in Imerge Limited. The consideration included a cash payment of #1.05m, and future incentive payments dependent upon performance. The BVCA valuation for Generics' share of Imerge at Q1 2005 was #1.3m. Johan Bjorklund, Generics' Chairman, commented: "I am pleased with both the development of the group during the first six months and the progress in the consulting and IP exploitation activities in particular. Our core technology development and consulting activity grew significantly, increasing fee income by 34% year-on-year whilst achieving a good and increasing profitability. SGAI Tech, our Hong Kong based joint venture, is performing ahead of forecast, adding new clients to its initial customer, Hornby plc. Income from licensing and royalty activities will improve with the next AutosheathTM milestone payment of $0.5m expected in the second half. While Q3 is likely to see a moderate seasonal reduction in revenue and sales run-rate, the order book and sales processes are now strong enough to sustain the ongoing growth in the technology consulting and IP business. Within our venturing activity during the first half we have received industry accolades for our spinout companies, CMR Fuel Cells Ltd and Sphere Medical Holding Ltd, both of which have been successfully financed in the year to date. Various funding, IPO and disposal opportunities continue to be developed across the portfolio. The prospects for CMR and Sphere, in particular, are strong." Enquiries: The Generics Group AG (44) 1223 875200 Martin Frost www.genericsgroup.com Simon Davey
waldron: RNS Number:7324J Generics Group AG 15 March 2005 15 March 2005 THE GENERICS GROUP AG ('GENERICS') PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2004 Generics, a leading integrated technology consulting, development and investment organisation, today announces its preliminary results for the year ended 31 December 2004. Highlights: * Turnover from continuing operations increased by 17 % to #15.7m (2003: #13.4m) * Operating expenses reduced by 15 % to #19.3m (2003: #22.7m) * Scientific Generics returned to profitability and growth during the course of 2004 with strong sales performance in USA and Germany * Total recognised losses relating to the year of #1.8m (2003: #10.2m) with adjusted loss per share of 1.0 pence (2003: loss of 9.2 pence), including expensed costs in spin-out and associated companies of #3.5m (2003: #6.4m). Loss before tax and minority interests of #2.9m (2003: #11.1m) * Successful refinancing of Atraverda Ltd during Q4 2004, raising #4.4m over three tranches, including a grant of #0.9m. A gain of #0.5m has been accounted for in the statement of total recognised gains and losses * Multi-year licence deal signed in respect of AutosheathTM needle-stick prevention technology * Sale of Generics' investment in the automotive activities within Sensopad Technologies Ltd for consideration of #1.2m during Q1 2004, and downstream royalty agreement * Year-end portfolio BVCA valuation of #11.6m (2003: #11.1m) * Net assets per share of 9.3 pence at year end (2003: 10.2* pence) before taking into account the BVCA portfolio valuation uplift equivalent to 2.9 pence per share (2003: 3.6* pence) * Assumes Rights Issue occurred at 31 December 2003 * #7.3m raised via a fully underwritten Rights Issue following the EGM in May 2004 * Creation of Hong Kong subsidiary - SGAI Ltd completed in Q1 2005 - to extend the design and development capability of our consulting operation into manufacturing Gordon Edge, Generics' Chairman, commented: "I am pleased to announce that at the end of 2004 our technology consulting and development activities have returned to profitability and a number of our investments including Sphere, CMR and Atraverda are making good commercial progress. During the year we sold the automotive interests of Sensopad Technologies to TT electronics plc and successfully refinanced the battery activities in Atraverda. This enabled the Group to reduce the total recognised losses for the year substantially from #10.2m in 2003 to #1.8m. The Group successfully completed a Rights Issue in June 2004 raising #7.3m. The additional cash resources together with the recovery in our technology consulting and development activities now places the Group in a robust position to build on the progress achieved in 2004. Scientific Generics ended the year with a profitable fourth quarter and a strong order book carried forward into 2005, having made excellent progress in Germany and the USA during the year. Our German office was opened 2 years ago to provide a focus for sales and operating in the German marketplace which accounts for approximately one-third of our sales. During the year we also concluded a substantial development contract and licence of our AutosheathTM needle stick prevention technology. High-quality technology innovation and design remains a hallmark of our business. We were therefore delighted at the end of the year when Scientific Generics was highly commended for its design collaborations on two world firsts at the recent US 2005 International CES Innovations Design and Engineering Awards. Working with St Jude Medical we helped to develop Housecall PlusTM, the world's first monitoring system to transmit complex implantable defibrillator data. We were also commissioned by Boardbug to design and develop a multi-functional mobile monitor, the Boardbug Baby and Child MonitorTM. This innovative form of child safety uses unique digital technology and won the 'Best of Innovation' Award in the Personal Electronics category. After the year-end we announced the launch of SGAI, our Hong Kong joint venture with Automatic International Ltd ('AIL'), established to provide an integrated end-to-end research, development and manufacturing capability. Through SGAI, together with AIL and its parent company Automatic Manufacturing Ltd, we will leverage the combined benefits and Hong Kong's strong intellectual property laws and its proximity to mainland China for the provision of a range of flexible, efficient and secure product development and manufacturing services to both new and existing clients. Within our investment portfolio, the recent commercial progress of Sphere Medical Holding, CMR Fuel Cells and Atraverda has been encouraging. Each of these portfolio companies is addressing very large market opportunities. Atraverda has developed an innovative lead acid battery design using EbonexTM bipolar membranes. The size of the global lead acid battery market is estimated at $16.2 billion per year, growing steadily each year and the smaller and more efficient Atraverda batteries are expected to be in high demand. CMR Fuel Cells, created to exploit a revolutionary flow-through fuel cell using mixed reactants, was spun out in Q1 2004 with The Carbon Trust and Conduit Ventures as Generics' partners. CMR's patented technology involves electrochemical devices, which convert fuel directly into electricity at high efficiency rates and have the potential for higher power storage capacity. Sphere Medical Ltd was established in a venture with Siemens to develop and market a new generation of monitoring and diagnostic products for patients. Our investment and technology consulting activities are on a firmer footing than at any time in the last 3 years." Enquiries: The Generics Group AG (44) 1223 875200 Martin Frost Managing Director www.genericsgroup.com Simon Davey CEO, Scientific Generics Hansard Communications (44) 207 2451100 Adam Reynolds Andy Tan
Genuit share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211208 08:08:55